{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:43:54Z","timestamp":1792046634052,"version":"4.4.0"},"reference-count":57,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mBio"],"published-print":{"date-parts":[[2022,8,30]]},"abstract":"<jats:p>The recent authorization of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, such as Paxlovid, has ushered in a new era of the COVID-19 pandemic. The emergence of new variants, as well as the selective pressure imposed by antiviral drugs themselves, raises concern for potential escape mutations in key drug binding motifs.<\/jats:p>","DOI":"10.1128\/mbio.00869-22","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:00:50Z","timestamp":1657702850000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":90,"title":["Genetic Surveillance of SARS-CoV-2 M\n                    <sup>pro<\/sup>\n                    Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid"],"prefix":"10.1128","volume":"13","author":[{"given":"Jonathan T.","family":"Lee","sequence":"first","affiliation":[{"name":"Vaccine Research &amp; Development, Pfizer Inc., Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Medicine Design, Worldwide Research &amp; Development, Pfizer Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Gribenko","sequence":"additional","affiliation":[{"name":"Vaccine Research &amp; Development, Pfizer Inc., Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-1372","authenticated-orcid":false,"suffix":"Jr.","given":"B. Scott","family":"Perrin","sequence":"additional","affiliation":[{"name":"Digital R&amp;D Creation Center, Pfizer Digital, Pfizer Inc., Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Vaccine Research &amp; Development, Pfizer Inc., Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Cardin","sequence":"additional","affiliation":[{"name":"Vaccine Research &amp; Development, Pfizer Inc., Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Liberator","sequence":"additional","affiliation":[{"name":"Vaccine Research &amp; Development, Pfizer Inc., Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Vaccine Research &amp; Development, Pfizer Inc., Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8865-7351","authenticated-orcid":true,"given":"Li","family":"Hao","sequence":"additional","affiliation":[{"name":"Vaccine Research &amp; Development, Pfizer Inc., Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05762-w"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102433"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-3-595"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12936"},{"key":"e_1_3_2_8_2","unstructured":"WHO. 2022. Tracking SARS-CoV-2 variants. World Health Organization Geneva Switzerland. https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-021-00408-x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.acz9879"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01678-y"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.1c00449"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01063"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1085658"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01461"},{"key":"e_1_3_2_17_2","unstructured":"Food and Drug Administration. 2021. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. U.S. Food and Drug Administration Washington D.C. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/gch2.1018"},{"key":"e_1_3_2_19_2","unstructured":"Hill SC Perkins M von Eije KJ (ed). 2021. Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health. World Health Organization Geneva Switzerland. https:\/\/www.who.int\/publications\/i\/item\/9789240018440."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9051094"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105033"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep22677"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02114-07"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-013-2841-3"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0030324"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2223-y"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01294-w"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03412-7"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.006"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01318-5"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03693-y"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102017"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.036"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8178170"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5560070103"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191381798"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101941"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2006.05130.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88630-9"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb3405"},{"key":"e_1_3_2_41_2","unstructured":"Yazdani S. 2020. Back to SARS-CoV-2 main protease: calculating the change in Gibbs free energy (ddGbind) of two peptidomimetic aldehyde Inhibitors binding associated with genetic variations of SARS-CoV-2 main protease\u2014post17. Open Lab Notebooks. https:\/\/openlabnotebooks.org\/back-to-sars-cov-2-main-protease-calculating-the-change-in-gibbs-free-energy-ddgbind-of-two-peptidomimetic-aldehyde-inhibitors-binding-associated-with-genetic-variations-of-sars-cov-2-main-protease\/."},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"Gayvert K Copin R McKay S Setliff I Lim WK Baum A Kyratsous CA Atwal GS. 2021. Viral population genomics reveals host and infectivity impact on SARS-CoV-2 adaptive landscape. bioRxiv. doi:10.1101\/2021.12.30.474516.","DOI":"10.1101\/2021.12.30.474516"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Greasley SE Noell S Plotnikova O Ferre R Liu W Bolanos B Fennell K Nicki J Craig T Zhu Y Stewart AE Steppan CM. 2022. Structural basis for nirmatrelvir in vitro efficacy against the Omicron variant of SARS-CoV-2. bioRxiv. doi:10.1101\/2022.01.17.476556.","DOI":"10.1101\/2022.01.17.476556"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Rosales R McGovern BL Rodriguez ML Rai DK Cardin RD Anderson AS Group P Sordillo EM van Bakel H Simon V Garc\u00eda-Sastre A White KM. 2022. Nirmatrelvir molnupiravir and remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant. bioRxiv. doi:10.1101\/2022.01.17.476685.","DOI":"10.1101\/2022.01.17.476685"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105252"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","unstructured":"Ullrich S Ekanayake KB Otting G Nitsche C. 2022. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332). bioRxiv. doi:10.1101\/2021.11.28.470226.","DOI":"10.1101\/2021.11.28.470226"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00618-w"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","unstructured":"Rai DK Yurgelonis I McMonagle P Rothan HA Hao L Gribenko A Titova E Kreiswirth B White KM Zhu Y Anderson AS Cardin RD. 2022. Nirmatrelvir an orally active M pro inhibitor is a potent inhibitor of SARS-CoV-2 variants of concern. bioRxiv. doi:10.1101\/2022.01.17.476644.","DOI":"10.1101\/2022.01.17.476644"},{"key":"e_1_3_2_49_2","unstructured":"Food and Drug Administration. 2021. Fact sheet for healthcare providers: emergency use authorization for Paxlovid TM . U.S. Food and Drug Administration Washington D.C. https:\/\/www.fda.gov\/media\/155050\/download."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105247"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-595"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(05)80360-2"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00078-5"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty407"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkf436"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msy096"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msaa069"}],"container-title":["mBio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mbio.00869-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mbio.00869-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T09:18:38Z","timestamp":1661851118000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mbio.00869-22"}},"subtitle":[],"editor":[{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8,30]]}},"alternative-id":["10.1128\/mbio.00869-22"],"URL":"https:\/\/doi.org\/10.1128\/mbio.00869-22","relation":{},"ISSN":["2150-7511"],"issn-type":[{"value":"2150-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"2022-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00869-22"}}